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Summary
 
Objective
 
Subclinical hypercortisolism (SH) is suggested to exert
a deleterious effect on bone. This effect and the role of gonadal status
in male subjects are not fully elucidated. We evaluated bone mineral
density (BMD) and prevalence of vertebral fractures in eugonadal
male subjects with adrenal incidentalomas (AI) and without SH.
 
Design
 
This 12-month observational multicentre study was
performed between January and December 2006 on inpatient basis
in three referral Italian centres.
 
Patients
 
Eighty-eight consecutive eugonadal male patients with AI
and 90 matched control subjects were studied.
 
Measurements
 
All subjects underwent the determination of BMD
by dual-energy X-ray absorptiometry at lumbar spine (LS) and
femoral neck (FN), and spinal radiograph. In AI patients SH was
diagnosed in the presence of two of the following: urinary free cortisol
> 193·1 nmol/l, cortisol after 1 mg dexamethasone suppression test
> 82·8 nmol/l, ACTH levels < 2·2 pmol/l.
 
Results
 
As compared to patients without SH (SH–, 
 
n
 
 = 66) and
controls, patients with SH (SH+, 
 
n
 
 = 22) had lower BMD at LS
(
 
Z
 
-score: SH+, –1·04 ± 1·84; SH–, 0·19 ± 1·34, Controls 0·20 ± 1·28,
 
P
 
 = 0·001 and FN (
 
Z
 
-score: SH+, –0·63 ± 1·01; SH–, 0·01 ± 1·01,
Controls 0·26 ± 1·06, 
 
P
 
 = 0·002) and higher prevalence of fractures
(SH+, 72·7%; SH–, 21·2%, Controls 20·0%, 
 
P
 
 = 0·0001). Multivariable
analyses showed that SH was associated to BMD at LS (
 
β
 
 = –0·378,
 
P
 
 = 0·0001) and vertebral fractures (OR = 7·81, 95% CI 1·96–31·17,
 
P
 
 = 0·004).
 
Conclusion
 
In eugonadal male patients with AI, SH is associated
with low BMD and high prevalence of vertebral fractures.
(Received 28 December 2007; returned for revision 18 January 2008; 
 
finally revised 13 March 2008; accepted 20 May 2008)
 
Introduction
 
Incidentally discovered adrenal masses (adrenal incidentalomas, AI)
are diagnosed with increasing frequency in patients evaluated by
imaging techniques for unrelated disorders. The great majority of
these lesions are benign adrenocortical adenomas.
 
1
 
 Although by
definition, AI are not associated with clinical signs of hormonal
hypersecretion, some AI patients may show a subtle degree of cortisol
excess, commonly defined as ‘subclinical hypercortisolism’ (SH).
 
2,3
 
This condition has been suggested to be associated to several com-
plications, including bone loss, which is a typical feature, even not
specific, of overt cortisol excess.
 
4
 
Indeed, most of the previous studies,
 
5–12
 
 even not all,
 
13–15
 
 strongly
suggested a possible negative effect of SH on bone. Nevertheless, data
about the most common complication of bone loss, such as vertebral
fractures, are scarce. The only study focused on this topic found a
higher proportion of vertebral fractures in AI female patients with
SH,
 
12
 
 while no study has been performed so far on vertebral fractures
in male patients with and without SH. This point seems of utmost
importance as the presence of vertebral fractures is a strong predictor
of future fractures.
 
16
 
 Thus, the finding of reduction of bone mass
and/or the presence of vertebral fractures may help to address the
treatment of choice in AI patients with SH.
In the present study we evaluated the spinal and femoral bone
mineral density (BMD) and the prevalence of vertebral fractures in
88 eugonadal male AI patient with and without SH.
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Subjects and methods
 
Subjects
 
Eighty-eight consecutive male patients with AI were enrolled from
January to December 2006 in three referral Italian centres ‘Casa Sollievo
della Sofferenza’ Scientific Institute in San Giovanni Rotondo, ‘San
Giuseppe-Milanocuore-AFaR’ Hospital and ‘Fondazione Ospedale
Maggiore Policlinico, Mangiagalli e Regina Elena’ Scientific Institute
in Milan.
We included only male subjects in order to avoid the possible
confounding gender-related effects on the skeleton.
 
17
 
 Diagnosis of
AI was based on the detection of a unilateral adrenal mass by non-
invasive imaging methods of the abdomen, performed for unrelated
disease. The exclusion criteria were: (i) past or current history of
hypogonadism (testosterone levels < 9·4 nmol/l)
 
18
 
 and of other
diseases known to affect bone metabolism (i.e. primary or secondary
hyperparathyroidism, thyrotoxicosis, bowel diseases, chronic renal
failure, chronic hepatic disease, depression, alcoholism, eating disorders,
rheumatologic or haematological diseases); (ii) administration of
drugs influencing bone, cortisol and dexamethasone (Dex) meta-
bolism or cortisol secretion; (iii) signs or symptoms specific of cortisol
excess (moon facies, striae rubrae, skin atrophy, buffalo hump).
On the basis of the presence or absence of SH, patients were
divided into Group SH+ (
 
n
 
 = 22) and SH– (
 
n
 
 = 66), respectively.
The diagnosis of SH was based on the presence of two out of the
following three alterations of hypothalamic–pituitary–adrenal (HPA)
axis secretion: (i) urinary free cortisol (UFC) levels > 193·1 nmol/l,
that is, the cut off of both our own and international
 
19
 
 normal
reference values; (ii) morning ACTH levels < 2·2 pmol/l; (iii) serum
cortisol levels at 09·00 a.m. after 1-mg Dex suppression test (cortisol
after Dex) > 82·8 nmol/l.
No subject had evidence of metastatic diseases. At computed
tomography (CT) all adrenal masses were homogeneous, hypodense
and well shaped, features consistent with the diagnosis of adrenocortical
adenomas. No CT scan was performed for malignancy staging.
Patients from group SH+ showed a higher mean diameter of adrenal
masses than those from group SH–, even if without reaching statis-
tical significance (mean ± SD, 3·0 ± 1·1 
 
vs.
 
 2·5 ± 1·1 cm, 
 
P
 
 = 0·066;
range 1·0–5·0 and 1·0–6·4 cm, respectively). Five patients whose AI
was higher than 4·0 cm had previously refused surgery and were sent
to our Departments to assess the possible presence of hormonal
hypersecretion. In all patients the diagnosis of pheochromocytoma
and aldosteronoma was excluded by appropriate hormonal (24-h
urinary cathecolamines and plasma renin activity and aldosterone
after 3 h of upright position) and clinical determinations.
Because the inpatient status can increase cortisol secretion, during
the same time a control group of 90 male inpatients matched for age
and BMI was recruited. These subjects were consecutively enrolled
on the basis of the above-mentioned inclusion criteria from our
outpatients clinics where they referred for unrelated diseases (simple
goiter with normal thyroid function).
In all subjects data about the presence of type 2 diabetes and/or
hypertension were obtained. Patients with confirmed fasting plasma
glucose level 
 
≥
 
 7·0 mmol/l) or with casual or during an oral glucose
tolerance test plasma glucose concentration 
 
≥
 
 11·1 mmol/l were
defined as diabetics. Subjects with systolic blood pressure
 
≥
 
 130 mmHg and/or diastolic blood pressure 
 
≥
 
 85 mmHg and/or on
antihypertensive treatment were defined as hypertensive.
All subjects gave their witnessed informed consent before entering
the study, which was approved by local ethical committees and in
accordance with Helsinki Declaration II. 
 
Methods
 
All samples were taken from all patients at the same time of day.
Serum and urinary samples were collected and stored at –20 
 
°
 
C until
assayed. In all patients serum ACTH levels (mean of three determi-
nations at 20-min intervals) were measured by IRMA (BRAHMS
Diagnostica GmbH, Berlin, Germany), serum cortisol and UFC levels
(after dichloromethane extraction) were determined immuno-
fluorimetrically by TDX-FLX Abbott, GmbH, Diagnostika kits
(Wiesbaden-Delkenheim, Germany) and dehydroepiandrosterone
(DHEA-S) and testosterone levels by chemiluminescence (Immulite,
Diagnostic Products Corporation, Los Angeles, CA). The intra- and
interassay coefficients of variation for all assays were < 5% and 10%,
respectively.
In all patients spinal L1–L4 BMD was measured by dual-energy
X-ray absorptiometry (DXA) (Hologic Discovery, Watham MA) at
spine (DXA L1–L4, 
 
in vivo
 
 precision 1·0%) and total and femoral
neck (FN) (
 
in vivo
 
 precision 1·8% and 2·3%, respectively). Individual
BMD values were expressed as SD units (
 
Z
 
-values) in relation
to reference population of our Centre.
 
20
 
 Conventional spinal radiograph
in lateral (T4–L4) and antero-posterior (AP) projection (L1–L4)
were obtained in all subjects with standardized technique. Two
trained radiologists, who were blinded to BMD and hormonal data,
independently reviewed the radiographs. Vertebral fractures were
diagnosed on visual inspection using the semiquantitative visual
assessment (SQ), previously described by Genant 
 
et al
 
.
 
21
 
 According
to this technique, fractures assessed on lateral thoracolumbar spine
radiographs were defined as reductions of more than 20% in
anterior, middle or posterior vertebral height. From lateral spine
radiographs, each vertebra is visually assessed as intact (SQ Grade 0)
or as having approximately mild (20–25% compression), moderate
(25–40% compression), or severe (> 40% compression) deformity
(SQ Grades 1, 2 and 3, respectively). The radiologists discussed
questionable cases to agree on a diagnosis; the interrate reliability
between the two radiologists was good (
 
κ
 
 = 0·86).
 
Statistical analysis
 
Statistical analysis was performed by 
 
spss
 
 version 12·0 statistical
package (SPSS Inc., Chicago, IL). The results are expressed as
mean ± SD.
Comparison of continuous variables among the different groups
was performed using one-way 
 
anova
 
 and Bonferroni posthoc analysis.
Categorical variables were compared by 
 
χ
 
2
 
 test. The associations between
indexes of cortisol secretion and bone mass were tested by either
Pearson Product Moment or Spearman correlation as appropriate.
In all patients multivariate linear regression analysis was used to
evaluate the influence of SH on BMD after adjusting for body mass
index (BMI), testosterone, DHEA-S levels.
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In all patients, logistic regression analysis assessed the association
between the presence of fractures (dependent variables, expressed
as categorical variable) and independent variables: age, BMI,
DHEA-S, testosterone, presence of SH and spinal BMD (expressed
as 
 
Z
 
-score).
 
P
 
-values of < 0·05 were considered significant.
 
Results
 
Clinical characteristics of patients with and without SH and controls
are reported in Table 1. Patients with SH, without SH and controls
were comparable for age, BMI and testosterone levels (Table 1). As
expected, cortisol after Dex and UFC levels were higher, while ACTH
and DHEA-S levels lower in SH+ than in SH– patients (Table 1). The
proportion of patients with hypertension and type 2 diabetes was
higher in SH+ than in SH– patients (Table 1). 
Patients with SH had lower BMD at lumbar spine (LS) and FN
as compared to those without SH and controls (Table 1). The
proportion of patients with osteoporosis (defined on the basis of the
presence of BMD 
 
T
 
-score 
 
≤
 
 –2·5 and/or vertebral fractures) and with
vertebral fractures (Table 1 and Fig. 1) was higher in SH+ patients
than in SH– and control subjects. All vertebral fractures were
asymptomatic. The 40·9% of fractured patients with SH had a BMD
measured at any site that, according to the World Health Organiza-
tion densitometric criteria,
 
22
 
 was normal or ‘osteopenic’ (BMD 
 
T
 
-score
> –2·5); this proportion was higher in SH+ as compared to SH–
(18·2%, 
 
P
 
 = 0·047) and control subjects (15·6%, 
 
P
 
 = 0·016) (Table 1
and Fig. 2).
Bivariate correlation analysis showed that there is an overall
negative correlation between LS BMD and UFC levels (
 
R
 
 =
 
 –
 
0·30,
 
P
 
 = 0·005). Multivariate linear regression analyses showed that LS
BMD was inversely associated to UFC levels and also to the presence
Table 1. Clinical characteristics of patients and controls
Control subjects 
(n = 90)
SH– patients 
(n = 66)
SH+ patients 
(n = 22)
Age (years) 61·8 ± 14·2 60·9 ± 12·9 65·8 ± 10·7
(23·0–90·0) (21·0–83·0) (42·0–86·0)
BMI (kg/m2) 27·7 ± 3·2 28·1 ± 3·1 28·5 ± 3·2
(21·4–36·7) (22·9–38·1) (24·6–37·1)
Testosterone (nmol/l) 17·5 ± 5·6 17·9 ± 6·3 16·1 ± 5·3
(10·9–30·8) (10·5–35·4) (10·5–31·2)
Urinary free cortisol (nmol/24 h) – 133·6 ± 61·3 201·2 ± 83·6*
(41·4–327·1) (64·3–438·8)
Cortisol after Dex (nmol/l) – 46·9 ± 24·8 124·2 ± 77·3*
(13·8–173·9) (38·6–358·8)
ACTH (pmol/l) – 4·1 ± 0·3 1·7 ± 0·8*
(0·24–3·2) (0·5–3·6)
DHEA-S (μmol/l) – 2·6 ± 2·2 1·4 ± 1·0†
(0·4–10·0) (0·4–4·0)
Lumbar spine BMD (Z-score) 0·20 ± 1·28 0·19 ± 1·34 –1·04 ± 1·84‡
(–2·30–2·90) (–2·80–3·60) (–4·50–4·10)
Femoral neck BMD (Z-score) 0·26 ± 1·06 0·01 ± 1·01 –0·63 ± 1·01§¶
(–2·30–2·90) (–2·8–2·1) (–2·5–1·5)
Subjects with osteoporosis§§ (%) 15 12 9§††
(16·7) (18·2) (40·9)
Subjects with vertebral fractures (%) 18 14 16‡
(20·0) (21·2) (72·7)
Subjects with vertebral fractures and BMD T-score > –2·5 14 12 9§‡‡
(15·6) (18·2) (40·9)
Subjects with hypertension (%) 43 28 16**
(47·8) (42·4) (72·7)
Subjects with type 2 diabetes (%) 19 13 10**
(21·1) (19·7) (45·5)
Data are expressed as mean ± SD with range in parenthesis or, absolute number with percentage in parenthesis.
*P = 0·001 vs. SH– patients, P = 0·016 vs. SH– patients, ‡P = 0·001 vs. SH– patients and control subjects, §P = 0·047 vs. SH– patients, ¶P = 0·001 vs. control 
subjects, **P = 0·025 vs. SH– patients, ††P = 0·032 vs. control subjects, ‡‡P = 0·016 vs. control subjects.
Cortisol after Dex, serum cortisol after 1-mg dexamethasone suppression test; BMD, bone mineral density measured by dual X-ray absorptiometry; 
SH, subclinical hypercortisolism was diagnosed in presence of two out of the following: cortisol after Dex > 82·7 nmol/l, urinary free cortisol levels > 193·0 nmol/
24h, serum ACTH levels < 2·2 pmol/l.
§§Osteoporosis: BMD T-score less than –2·5 at any measured site and/or vertebral fractures.
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of SH (
 
β
 
 = –0·338, 
 
P
 
 = 0·02 and 
 
β
 
 = –0·378, 
 
P
 
 = 0·0001, respectively)
after adjustment for age, BMI, testosterone and DHEA-S levels.
The presence of vertebral fractures was significantly associated to
the presence of SH also when age, BMI, DHEA-S, testosterone levels
and LS BMD were added to the model as shown by logistic regression
analysis (Table 2).
 
Discussion
 
Our study confirms that in male patients with AI and SH bone mass
is reduced and demonstrates that in these patients the proportion
of vertebral fractures is increased. BMD and the presence of fractures
are related to the degree of cortisol secretion. This negative effect of
SH on bone is present despite the eugonadal status of patients.
In the recent years, the term ‘subclinical hypercortisolism’ has been
used to define a condition of subtle hypercortisolism characterized
by altered biochemical parameters of HPA axis in the absence of the
classical signs or symptoms of overt cortisol excess.
 
3
 
 This condition
has been described in up to 20% of patients bearing an AI.
 
2
 
 In fact,
in spite of the definition of ‘subclinical’ hypercortisolism, this
condition of subtle cortisol excess has been described to be associated
with the presence of classic, even not specific, complications of overt
cortisol excess as obesity, type 2 diabetes, hypertension and bone
loss.
 
4–12,23–25
 
Regarding bone involvement in the presence of SH, no data are
reported so far regarding vertebral fractures in male patients. Thus,
the most important finding of the present investigation is that in
male patients with AI and SH the proportion of vertebral fractures
is increased. Furthermore, the negative effect of SH on bone is
present in spite of the eugonadal status of patients. This is in keeping
with previous data showing a reduced BMD in eugonadal male
patients with AI and SH,
 
9
 
 and with previous findings in eugonadal
female patients with subclinical
 
8,12
 
 and overt cortisol excess.
 
26,27
 
However, the prevalence of vertebral fractures found in this study in
eugonadal male patients (72·7%) is somewhat higher as compared
to that found in eugonadal female subjects (42·9%) in an our pre-
vious study.
 
12
 
 In our opinion this discrepancy could be due to the
different mean age of the two samples (66 and 43 years, respectively)
and therefore to the possible difference in the disease duration.
Interestingly, in our patients the presence of vertebral fractures is
associated with the presence of SH regardless of age, BMI, testoster-
one and DHEA-S levels, and of utmost importance, bone mass.
Fig. 1 Prevalence of vertebral fractures in eugonadal male patients with 
adrenal incidentalomas in relation to the presence of subclinical 
hypercortisolism.
Table 2. Odds ratio for detecting vertebral fracture for potential risk factors 
using multivariable logistic regression model
Odds ratio P value 95% CI
Age (10 year increase) 2·20 0·009 1·21–3·97
BMI (1 SD increase) 0·57 0·155 0·70–3·84
DHEA-S (1 SD increase) 0·97 0·960 0·33–3·33
Testosterone (1 SD increase) 0·92 0·841 0·47–0·56
SH (presence vs. absence) 7·24 0·002 2·13–24·60
Lumbar spine BMD (1 SD increase) 0·41 0·050 1·01–5·88
SD, standard deviation; BMI, body mass index; DHEA-S, 
dehydroepiandrosterone levels; SH, subclinical hypercortisolism was 
diagnosed in presence of two out of the following: cortisol levels after 1-mg 
dexamethasone suppression test higher than 82·8 nmol/l, urinary free 
cortisol levels higher than 193·0 nmol/24 h, serum ACTH levels lower than 
2·2 pmol/l.
The logistic regression analysis assessed the association between the presence 
of fractures (dependent variables, expressed as categorical variable) and 
independent variables: age, BMI, DHEA-S, testosterone, presence of SH and 
spinal BMD (expressed as Z-score). 
Fig. 2 Prevalence of vertebral fractures in eugonadal male patients with 
adrenal incidentalomas and normal or ‘osteopenic’ bone mineral density in 
patients with and without subclinical hypercortisolism.
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Moreover, in all subjects vertebral fractures were asymptomatic and
the 40% of fractured patients with SH had a BMD measured at any
site that, according to the World Health Organization densitometric
criteria,
 
22
 
 was normal or ‘osteopenic’ (BMD 
 
T
 
-score > –2·5). As
vertebral fractures are strong predictors of future fracture risk,
 
16
 
these findings suggest that in patients with AI and SH conventional
spinal radiograph is mandatory even in the absence of hypogonadism,
back pain or reduced BMD. In addition, the proportion of subjects
with BMD 
 
T
 
-score > –2·5, but with vertebral fractures, was higher
in SH+ than in SH– patients and in controls (Fig. 2). This finding
suggests that, similarly to what is reported in the presence of overt
cortisol excess, also in SH the risk of fractures is increased for a given
 
T
 
-score.
 
4
 
 This may be due to the fact that cortisol excess affects not
only bone mass but also bone quality.
 
4
 
Finally, patients with SH showed a higher prevalence of hyper-
tension and diabetes as compared to patients without SH. These
findings confirm the observations from several previous studies,
 
23–25
 
and reinforce the idea that the condition of subtle cortisol excess,
even if ‘subclinical’, may cause the same consequences of overt
cortisol excess. However, the cross-sectional design of our study
allows us to show association but not causality. Nevertheless, given
the well recognized negative effect of cortisol excess on bone, a causative
role of SH on reduction of bone mass and increase of fractures is
likely. In addition, a tight link between SH and low bone mass and
fractures has been recently confirmed by a study reporting a high
prevalence of SH in patients with established osteoporosis.
 
28
 
In summary, although caution is needed considering the low
statistical power of the study, our data seem to indicate that in
eugonadal male patients with adrenal incidentalomas subclinical
hypercortisolism is associated with low bone mass and high proportion
of vertebral fractures and bone mass and presence of vertebral
fractures are related to the degree of cortisol secretion. Prospective
longitudinal intervention studies are needed to confirm the causative
role of SH on bone loss and risk of fractures.
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